Cargando…
Hepatitis C virus management: potential impact of nanotechnology
Around 170–200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3–5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had b...
Autores principales: | Elberry, Mostafa H., Darwish, Noureldien H. E., Mousa, Shaker A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414367/ https://www.ncbi.nlm.nih.gov/pubmed/28464951 http://dx.doi.org/10.1186/s12985-017-0753-1 |
Ejemplares similares
-
Novel combined single dose anti-hepatitis C therapy: a pilot study
por: Shiha, Gamal, et al.
Publicado: (2021) -
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study
por: Shiha, Gamal, et al.
Publicado: (2019) -
Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management
por: Sudha, Thangirala, et al.
Publicado: (2021) -
Senescent Colon and Breast Cancer Cells Induced by Doxorubicin Exhibit Enhanced Sensitivity to Curcumin, Caffeine, and Thymoquinone
por: El-Far, Ali H., et al.
Publicado: (2020) -
Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1
por: Darwish, Noureldien H.E., et al.
Publicado: (2016)